A recent clinical trial indicates that a personalized cancer vaccine, tailored to each individual patient, has reduced the risk of death or skin cancer recurrence by 42% when administered alongside standard immunotherapy. This milestone in precision medicine also decreased the likelihood of melanoma spreading by 38% over a two-year period compared to immunotherapy alone. The trial involved 1137 adults who underwent tumor removal surgery and were treated with the immunotherapy drug 'Keytruda'. Developers Moderna and MSD are currently testing this approach on other cancer types, including lung, bladder, and kidney cancers. Independent experts have praised the results but emphasize the need for long-term studies to confirm improvements in patient survival rates.